Darrell E. White, MD, joins I. Paul Singh, MD, on a special episode of Innovation Journal Club dedicated to the topic of work-life balance. According to Dr. White, the key to achieving balance lies not in separating professional responsibilities and…
Advocacy does not always mean fighting back. Often, it means clearly documenting medical necessity, communicating clinical rationale so payers can understand, and being strategic about…
Missed diagnoses can put patients at risk for serious eye complications and even be life-threatening. Three YOs provide vital tips for spotting and managing these…
Steroid-induced glaucoma can present a number of issues, most notably increased IOP. Several ophthalmologists discussed identifying when and why this occurs and how to react…
With the ideal mix of retinal coverage and operational convenience, the retinal imaging space is prime for innovation
Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several malignancies.
With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery
STODS can negatively impact patient satisfaction and surgical outcomes. Surgeons can reduce patient burden by identifying at-risk patients; optimizing the ocular surface before surgery; adopting…
The eye rubbing response to Demodex blepharitis may be causing other ocular issues, but fortunately, it is easy to identify with a simple slit-lamp examination.
To investigate regional variations in guttae distribution in Fuchs endothelial corneal dystrophy (FECD) and evaluate its relationship with anatomical ultraviolet (UV) protection by the eyelid.
Harrow acquired the U.S. commercial rights for Byqlovi through a licensing agreement with Formosa Pharmaceuticals, according to a press release.
